Comparison of three-year clinical outcomes between sirolimus-versus paclitaxel-eluting stents in diabetic patients: Prospective randomized multicenter trial

Soon Jun Hong, Moo Hyun Kim, Kwang Soo Cha, Hun Sik Park, Shung Chull Chae, Seung Ho Hur, Hyeon Cheol Gwon, Jang Ho Bae, Do-Sun Lim

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Three-year follow-up of major adverse cardiovascular event (MACE) (death, nonfatal myocardial infarction, target lesion revascularization) and the predictors of MACEs in diabetic patients after sirolimus-eluting stent (SES) or paclitaxel-eluting stent (PES) implantation have not been reported. Methods: Diabetic patients with de novo coronary lesions (169 patients with 190 lesions) were randomly assigned prospectively to either SES or PES. Results: Baseline characteristics were similar between the two groups. The rates of MACEs [5.9% (n = 5) in the SES vs. 9.5% (n = 8) in the PES Group, P = 0.374] and definite stent thrombosis [1.2% (n = 1) in the SES vs. 3.6% (n = 3) in the PES Group, P = 0.368] were similar in the two groups during the three-year follow-up. Multivariate logistic analysis showed that insulin treatment was the only independent predictor of MACE [odds ratio (OR) 8.60, 95% confidence interval (CI) 3.25-22.76, P < 0.001] and target vessel revascularization (TVR) (OR 9.50, 95% CI 3.07-29.44, P < 0.001) during the three-year follow-up. Conclusions: The rates of MACEs, TVR, and stent thrombosis during the three-year follow-up were similar in the SES and PES Groups. Insulin treatment was a main predictor of MACEs and TVR during the three-year follow-up after either SES or PES implantation.

Original languageEnglish
Pages (from-to)924-933
Number of pages10
JournalCatheterization and Cardiovascular Interventions
Volume76
Issue number7
DOIs
Publication statusPublished - 2010 Dec 1

Fingerprint

Sirolimus
Paclitaxel
Multicenter Studies
Stents
Thrombosis
Odds Ratio
Confidence Intervals
Insulin
Multivariate Analysis
Myocardial Infarction

Keywords

  • diabetes mellitus
  • drug-eluting stents
  • major adverse cardiac event
  • stent thrombosis
  • survival analysis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Radiology Nuclear Medicine and imaging

Cite this

Comparison of three-year clinical outcomes between sirolimus-versus paclitaxel-eluting stents in diabetic patients : Prospective randomized multicenter trial. / Hong, Soon Jun; Kim, Moo Hyun; Cha, Kwang Soo; Park, Hun Sik; Chae, Shung Chull; Hur, Seung Ho; Gwon, Hyeon Cheol; Bae, Jang Ho; Lim, Do-Sun.

In: Catheterization and Cardiovascular Interventions, Vol. 76, No. 7, 01.12.2010, p. 924-933.

Research output: Contribution to journalArticle

Hong, Soon Jun ; Kim, Moo Hyun ; Cha, Kwang Soo ; Park, Hun Sik ; Chae, Shung Chull ; Hur, Seung Ho ; Gwon, Hyeon Cheol ; Bae, Jang Ho ; Lim, Do-Sun. / Comparison of three-year clinical outcomes between sirolimus-versus paclitaxel-eluting stents in diabetic patients : Prospective randomized multicenter trial. In: Catheterization and Cardiovascular Interventions. 2010 ; Vol. 76, No. 7. pp. 924-933.
@article{8ac3221aa37e41ceba41a216c094e62b,
title = "Comparison of three-year clinical outcomes between sirolimus-versus paclitaxel-eluting stents in diabetic patients: Prospective randomized multicenter trial",
abstract = "Background: Three-year follow-up of major adverse cardiovascular event (MACE) (death, nonfatal myocardial infarction, target lesion revascularization) and the predictors of MACEs in diabetic patients after sirolimus-eluting stent (SES) or paclitaxel-eluting stent (PES) implantation have not been reported. Methods: Diabetic patients with de novo coronary lesions (169 patients with 190 lesions) were randomly assigned prospectively to either SES or PES. Results: Baseline characteristics were similar between the two groups. The rates of MACEs [5.9{\%} (n = 5) in the SES vs. 9.5{\%} (n = 8) in the PES Group, P = 0.374] and definite stent thrombosis [1.2{\%} (n = 1) in the SES vs. 3.6{\%} (n = 3) in the PES Group, P = 0.368] were similar in the two groups during the three-year follow-up. Multivariate logistic analysis showed that insulin treatment was the only independent predictor of MACE [odds ratio (OR) 8.60, 95{\%} confidence interval (CI) 3.25-22.76, P < 0.001] and target vessel revascularization (TVR) (OR 9.50, 95{\%} CI 3.07-29.44, P < 0.001) during the three-year follow-up. Conclusions: The rates of MACEs, TVR, and stent thrombosis during the three-year follow-up were similar in the SES and PES Groups. Insulin treatment was a main predictor of MACEs and TVR during the three-year follow-up after either SES or PES implantation.",
keywords = "diabetes mellitus, drug-eluting stents, major adverse cardiac event, stent thrombosis, survival analysis",
author = "Hong, {Soon Jun} and Kim, {Moo Hyun} and Cha, {Kwang Soo} and Park, {Hun Sik} and Chae, {Shung Chull} and Hur, {Seung Ho} and Gwon, {Hyeon Cheol} and Bae, {Jang Ho} and Do-Sun Lim",
year = "2010",
month = "12",
day = "1",
doi = "10.1002/ccd.22369",
language = "English",
volume = "76",
pages = "924--933",
journal = "Catheterization and Cardiovascular Interventions",
issn = "1522-1946",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - Comparison of three-year clinical outcomes between sirolimus-versus paclitaxel-eluting stents in diabetic patients

T2 - Prospective randomized multicenter trial

AU - Hong, Soon Jun

AU - Kim, Moo Hyun

AU - Cha, Kwang Soo

AU - Park, Hun Sik

AU - Chae, Shung Chull

AU - Hur, Seung Ho

AU - Gwon, Hyeon Cheol

AU - Bae, Jang Ho

AU - Lim, Do-Sun

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Background: Three-year follow-up of major adverse cardiovascular event (MACE) (death, nonfatal myocardial infarction, target lesion revascularization) and the predictors of MACEs in diabetic patients after sirolimus-eluting stent (SES) or paclitaxel-eluting stent (PES) implantation have not been reported. Methods: Diabetic patients with de novo coronary lesions (169 patients with 190 lesions) were randomly assigned prospectively to either SES or PES. Results: Baseline characteristics were similar between the two groups. The rates of MACEs [5.9% (n = 5) in the SES vs. 9.5% (n = 8) in the PES Group, P = 0.374] and definite stent thrombosis [1.2% (n = 1) in the SES vs. 3.6% (n = 3) in the PES Group, P = 0.368] were similar in the two groups during the three-year follow-up. Multivariate logistic analysis showed that insulin treatment was the only independent predictor of MACE [odds ratio (OR) 8.60, 95% confidence interval (CI) 3.25-22.76, P < 0.001] and target vessel revascularization (TVR) (OR 9.50, 95% CI 3.07-29.44, P < 0.001) during the three-year follow-up. Conclusions: The rates of MACEs, TVR, and stent thrombosis during the three-year follow-up were similar in the SES and PES Groups. Insulin treatment was a main predictor of MACEs and TVR during the three-year follow-up after either SES or PES implantation.

AB - Background: Three-year follow-up of major adverse cardiovascular event (MACE) (death, nonfatal myocardial infarction, target lesion revascularization) and the predictors of MACEs in diabetic patients after sirolimus-eluting stent (SES) or paclitaxel-eluting stent (PES) implantation have not been reported. Methods: Diabetic patients with de novo coronary lesions (169 patients with 190 lesions) were randomly assigned prospectively to either SES or PES. Results: Baseline characteristics were similar between the two groups. The rates of MACEs [5.9% (n = 5) in the SES vs. 9.5% (n = 8) in the PES Group, P = 0.374] and definite stent thrombosis [1.2% (n = 1) in the SES vs. 3.6% (n = 3) in the PES Group, P = 0.368] were similar in the two groups during the three-year follow-up. Multivariate logistic analysis showed that insulin treatment was the only independent predictor of MACE [odds ratio (OR) 8.60, 95% confidence interval (CI) 3.25-22.76, P < 0.001] and target vessel revascularization (TVR) (OR 9.50, 95% CI 3.07-29.44, P < 0.001) during the three-year follow-up. Conclusions: The rates of MACEs, TVR, and stent thrombosis during the three-year follow-up were similar in the SES and PES Groups. Insulin treatment was a main predictor of MACEs and TVR during the three-year follow-up after either SES or PES implantation.

KW - diabetes mellitus

KW - drug-eluting stents

KW - major adverse cardiac event

KW - stent thrombosis

KW - survival analysis

UR - http://www.scopus.com/inward/record.url?scp=78649680330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649680330&partnerID=8YFLogxK

U2 - 10.1002/ccd.22369

DO - 10.1002/ccd.22369

M3 - Article

C2 - 20815045

AN - SCOPUS:78649680330

VL - 76

SP - 924

EP - 933

JO - Catheterization and Cardiovascular Interventions

JF - Catheterization and Cardiovascular Interventions

SN - 1522-1946

IS - 7

ER -